UroGen Debt Ratio from 2010 to 2025

URGN Stock

USD 9.46 0.17 1.83%

UroGen Pharma Debt Ratio yearly trend continues to be very stable with very little volatility. Debt Ratio is likely to grow to 0.53 this year. During the period from 2010 to 2025, UroGen Pharma Debt Ratio quarterly data regression pattern had sample variance of 0.07 and median of 0.01. View All Fundamentals

Debt Ratio

First Reported

2010-12-31

Previous Quarter

0.51

Current Value

0.53

Quarterly Volatility

0.25891331

Credit Downgrade

Yuan Drop

Covid

Check UroGen Pharma financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among UroGen Pharma's main balance sheet or income statement drivers, such as Depreciation And Amortization of 2.1 M, Interest Expense of 17.8 M or Selling General Administrative of 109.1 M, as well as many indicators such as Price To Sales Ratio of 5.71, Dividend Yield of 0.0 or Days Sales Outstanding of 98.77. UroGen financial statements analysis is a perfect complement when working with UroGen Pharma Valuation or Volatility modules.

Check out the analysis of UroGen Pharma Correlation against competitors.

To learn how to invest in UroGen Stock, please use our How to Invest in UroGen Pharma guide.

Latest UroGen Pharma's Debt Ratio Growth Pattern

Below is the plot of the Debt Ratio of UroGen Pharma over the last few years. It is UroGen Pharma's Debt Ratio historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in UroGen Pharma's overall financial position and show how it may be relating to other accounts over time.

Debt Ratio

10 Years Trend

Slightly volatile

Compare to Others All Fundamentals

Debt Ratio

Timeline

UroGen Debt Ratio Regression Statistics

	Arithmetic Mean	0.15
	Geometric Mean	0.03
	Coefficient Of Variation	167.46
	Mean Deviation	0.21
	Median	0.01
	Standard Deviation	0.26
	Sample Variance	0.07
	Range	0.7242
	R-Value	0.72
	Mean Square Error	0.03
	R-Squared	0.52
	Significance	0
	Slope	0.04
	Total Sum of Squares	1.01

UroGen Debt Ratio History

	2025	0.53
	2024	0.51
	2023	0.56
	2022	0.73
	2021	0.003324
	2020	0.0123

Other Fundumenentals of UroGen Pharma

Cash Flow To Debt Ratio

UroGen Pharma Debt Ratio component correlations

	Total Assets	Total Stockholder Equity	Net Tangible Assets	Net Debt	Retained Earnings	Accounts Payable	Total Liab	Total Current Assets	Common Stock	Property Plant Equipment	Long Term Debt	Short Term Investments	Long Term Debt Total	Capital Surpluse	Net Receivables	Current Deferred Revenue	Net Invested Capital	Net Working Capital	Capital Stock	Long Term Investments	Short Term Debt
Total Assets		-0.03	-0.16	-0.08	-0.87	0.8	0.78	0.99	0.96	0.69	0.92	0.78	0.75	0.88	0.91	0.64	0.0	0.91	0.79	-0.71	-0.39
Total Stockholder Equity	-0.03		0.99	-0.78	0.45	-0.01	-0.65	-0.12	-0.23	0.53	0.04	0.43	0.13	-0.13	-0.4	-0.56	0.87	-0.17	-0.44	0.47	0.46
Net Tangible Assets	-0.16	0.99		-0.76	0.53	-0.1	-0.75	-0.25	-0.35	0.45	-0.06	0.35	0.06	-0.21	-0.5	-0.69	0.83	-0.29	-0.55	0.53	0.52
Net Debt	-0.08	-0.78	-0.76		-0.18	-0.27	0.43	-0.06	-0.01	-0.49	-0.26	-0.51	-0.33	-0.08	0.12	0.36	-0.51	0.08	0.23	-0.11	-0.46
Retained Earnings	-0.87	0.45	0.53	-0.18		-0.71	-0.93	-0.9	-0.93	-0.45	-0.8	-0.49	-0.64	-0.92	-0.97	-0.7	0.44	-0.85	-0.89	0.94	0.43
Accounts Payable	0.8	-0.01	-0.1	-0.27	-0.71		0.6	0.83	0.8	0.43	0.88	0.84	0.85	0.78	0.76	0.41	-0.18	0.73	0.64	-0.56	-0.26
Total Liab	0.78	-0.65	-0.75	0.43	-0.93	0.6		0.83	0.87	0.18	0.67	0.31	0.47	0.73	0.94	0.85	-0.54	0.79	0.87	-0.83	-0.58
Total Current Assets	0.99	-0.12	-0.25	-0.06	-0.9	0.83	0.83		0.99	0.63	0.94	0.74	0.76	0.89	0.94	0.69	-0.11	0.9	0.82	-0.77	-0.41
Common Stock	0.96	-0.23	-0.35	-0.01	-0.93	0.8	0.87	0.99		0.56	0.92	0.66	0.72	0.88	0.96	0.74	-0.22	0.88	0.86	-0.83	-0.42
Property Plant Equipment	0.69	0.53	0.45	-0.49	-0.45	0.43	0.18	0.63	0.56		0.65	0.72	0.62	0.69	0.44	0.04	0.47	0.56	0.36	-0.43	0.04
Long Term Debt	0.92	0.04	-0.06	-0.26	-0.8	0.88	0.67	0.94	0.92	0.65		0.83	0.84	0.86	0.83	0.47	-0.09	0.75	0.66	-0.71	-0.24
Short Term Investments	0.78	0.43	0.35	-0.51	-0.49	0.84	0.31	0.74	0.66	0.72	0.83		0.74	0.68	0.58	0.14	0.33	0.64	0.37	-0.33	-0.09
Long Term Debt Total	0.75	0.13	0.06	-0.33	-0.64	0.85	0.47	0.76	0.72	0.62	0.84	0.74		0.77	0.63	0.26	-0.07	0.65	0.57	-0.56	-0.19
Capital Surpluse	0.88	-0.13	-0.21	-0.08	-0.92	0.78	0.73	0.89	0.88	0.69	0.86	0.68	0.77		0.88	0.46	-0.22	0.87	0.83	-0.86	-0.29
Net Receivables	0.91	-0.4	-0.5	0.12	-0.97	0.76	0.94	0.94	0.96	0.44	0.83	0.58	0.63	0.88		0.76	-0.36	0.87	0.87	-0.87	-0.42
Current Deferred Revenue	0.64	-0.56	-0.69	0.36	-0.7	0.41	0.85	0.69	0.74	0.04	0.47	0.14	0.26	0.46	0.76		-0.34	0.71	0.82	-0.56	-0.62
Net Invested Capital	0.0	0.87	0.83	-0.51	0.44	-0.18	-0.54	-0.11	-0.22	0.47	-0.09	0.33	-0.07	-0.22	-0.36	-0.34		-0.06	-0.36	0.55	0.13
Net Working Capital	0.91	-0.17	-0.29	0.08	-0.85	0.73	0.79	0.9	0.88	0.56	0.75	0.64	0.65	0.87	0.87	0.71	-0.06		0.93	-0.67	-0.55
Capital Stock	0.79	-0.44	-0.55	0.23	-0.89	0.64	0.87	0.82	0.86	0.36	0.66	0.37	0.57	0.83	0.87	0.82	-0.36	0.93		-0.78	-0.57
Long Term Investments	-0.71	0.47	0.53	-0.11	0.94	-0.56	-0.83	-0.77	-0.83	-0.43	-0.71	-0.33	-0.56	-0.86	-0.87	-0.56	0.55	-0.67	-0.78		0.27
Short Term Debt	-0.39	0.46	0.52	-0.46	0.43	-0.26	-0.58	-0.41	-0.42	0.04	-0.24	-0.09	-0.19	-0.29	-0.42	-0.62	0.13	-0.55	-0.57	0.27

Click cells to compare fundamentals

About UroGen Pharma Financial Statements

UroGen Pharma investors utilize fundamental indicators, such as Debt Ratio, to predict how UroGen Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.

	Last Reported	Projected for Next Year
Debt Ratio	0.51	0.53
Cash Flow To Debt Ratio	(0.69)	(0.72)

When determining whether UroGen Pharma offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of UroGen Pharma's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Urogen Pharma Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Urogen Pharma Stock:

How To Invest In UroGen

Details

Is UroGen Stock a good investment?

Details

What is UroGen Pharma's Net Worth?

Details

Largest Biotechnology Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

Check out the analysis of UroGen Pharma Correlation against competitors.

To learn how to invest in UroGen Stock, please use our How to Invest in UroGen Pharma guide.

You can also try the Portfolio Comparator module to compare the composition, asset allocations and performance of any two portfolios in your account.

Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of UroGen Pharma. If investors know UroGen will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about UroGen Pharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

(3.02)

Revenue Per Share

2.389

Quarterly Revenue Growth

0.209

Return On Assets

(0.21)

Return On Equity

(14.81)

The market value of UroGen Pharma is measured differently than its book value, which is the value of UroGen that is recorded on the company's balance sheet. Investors also form their own opinion of UroGen Pharma's value that differs from its market value or its book value, called intrinsic value, which is UroGen Pharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because UroGen Pharma's market value can be influenced by many factors that don't directly affect UroGen Pharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between UroGen Pharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if UroGen Pharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, UroGen Pharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

UroGen Debt Ratio from 2010 to 2025

Latest UroGen Pharma's Debt Ratio Growth Pattern

UroGen Debt Ratio Regression Statistics

UroGen Debt Ratio History

Other Fundumenentals of UroGen Pharma

UroGen Pharma Debt Ratio component correlations

About UroGen Pharma Financial Statements

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY